Home » INSPIRE ANNOUNCES DEVELOPMENT AND LICENSE AGREEMENT WITH BOEHRINGER INGELHEIM INTERNATIONAL
INSPIRE ANNOUNCES DEVELOPMENT AND LICENSE AGREEMENT WITH BOEHRINGER INGELHEIM INTERNATIONAL
Inspire Pharmaceuticals, Inc. announced today it has entered into a development
and license agreement with Boehringer Ingelheim International GmbH. Inspire
will acquire certain exclusive rights to develop and market an intranasal dosage
form of epinastine in the United States and Canada for the treatment or prevention
of rhinitis.
INS
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May